This document discusses the management of pregnancy and labor with anemia. It defines the severity of anemia according to WHO and ICMR guidelines. It outlines the steps to clinically assess and diagnose anemia, including common tests. Iron deficiency anemia is the most common type and is preventable through diet, supplementation, and treating causes like hookworm infection. Treatment options for anemia in pregnancy include oral or parental iron therapy, blood transfusion, and use of erythropoietin in severe cases. Management during labor focuses on making the patient comfortable while aiming for a vaginal delivery when possible. The document also reviews anemia caused by folate or B12 deficiency, thalassemia, and provides counseling points for pre
Iron deficiency anaemia in pregnancy- evidence based approachWafaa Benjamin
Iron deficiency is the most common deficiency state in the world, affecting more than 2 billion people globally.
Iron Depletion affects 20-40% of Egyptian women in childbearing period.
Effective management is needed to prevent adverse maternal and pregnancy outcomes, including the need for red cell transfusion.
There should be clear and simple recommendations for the diagnosis, treatment and prevention of iron deficiency in pregnancy and the postpartum period.
Universal iron supplementation in pregnancy is more suitable for our local protocol.
Haemoglopinopathy screening program for pregnant women is awaited.
Iron deficiency anaemia in pregnancy- evidence based approachWafaa Benjamin
Iron deficiency is the most common deficiency state in the world, affecting more than 2 billion people globally.
Iron Depletion affects 20-40% of Egyptian women in childbearing period.
Effective management is needed to prevent adverse maternal and pregnancy outcomes, including the need for red cell transfusion.
There should be clear and simple recommendations for the diagnosis, treatment and prevention of iron deficiency in pregnancy and the postpartum period.
Universal iron supplementation in pregnancy is more suitable for our local protocol.
Haemoglopinopathy screening program for pregnant women is awaited.
complete treatment guidelines about the iron deficiency anaemia.it gives information about all forms of treatment.information given is more than enough for a medical student
Anemia management of anemia in pregnancyDR MUKESH SAH
Treatment for Anemia
If you are anemic during your pregnancy, you may need to start taking an iron supplement and/or folic acid supplement in addition to your prenatal vitamins. Your doctor may also suggest that you add more foods that are high in iron and folic acid to your diet.
Please find the power point on Anemia in pregnancy. I tried to present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
complete treatment guidelines about the iron deficiency anaemia.it gives information about all forms of treatment.information given is more than enough for a medical student
Anemia management of anemia in pregnancyDR MUKESH SAH
Treatment for Anemia
If you are anemic during your pregnancy, you may need to start taking an iron supplement and/or folic acid supplement in addition to your prenatal vitamins. Your doctor may also suggest that you add more foods that are high in iron and folic acid to your diet.
Please find the power point on Anemia in pregnancy. I tried to present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
1. Management of pregnancy and
labour with anaemia
Speaker –Dr Sobhan Kumar Padhi (2nd year PG)
Moderator-Prof. Dr. Santosh Kumar Behera
2. SEVERITY OF ANAEMIA WHO (Hb in g/dl) ICMR (Hb in g/dl)
NORMAL >11 >11
MILD 10-10.9 10.0-10.9
MODERATE 7.0-9.9 7.0-10.0
SEVERE <7.0 <7.0
VERY SEVERE _ <4.0
1. Anaemia in pregnant women is defined as haemoglobin
concentration below 11 gm/dl(WHO)
2. Cut-off for 1st and 3rd trimester 11gm/dl,2nd trimester below 10.5
gm/dl(CDC)
3. Steps to approach an anaemic pregnancy
1 clinical and lab assesment for severity
2 typing
3 identify the cause
4 predisposing and precipitating factors
4. Clinical assessment
symptoms and signs- weakness, lightheadedness, headache, loss
of appetite, dysphagia, skin changes, nail changes ,ankle swelling,
dyspnoea on exertion, palpitations
history-
worm infestation,malabsorption ,excess menstrual loss, bleeding
disorder, chronic diseases,infections,bleeding PR or haematuria,bone
marrow suppression, endemic areas, genetics, previous history of
anemia, blood transfusion, etc.
8. IDA Anemia of
chronic
disease
Thalassemia Sidero-blastic
Severity Variable Mild Mild Variable
MCV Decreased Normal/
decreased
Decreased Normal/
decreased
S Ferritin Decreased Normal/
increased
Normal Increased
TIBC Increased Decreased Normal Normal
S Iron Decreased Decreased Normal Increased
Marrow iron - + + +
10. Diagnosis - Additional
•Serum Fe
•Total iron binding capacity(TIBC)
•Serum Ferritin
•Serum transferrin saturation
•Hb electrophoresis
•Bone marrow examination
11. Newer investigations
• Soluble Serum transferrin receptors(ELISA)
• Transferrin receptor/ ferritin index
• Reticulocyte indices
–automated counting of reticulocytes, count of <26pg/ cell is
a strong predictor of IDA
–Reticulocyte production index
• Red cell zinc protoporphyrin level(Reserved test)
• Free erythrocyte protoporphyrin
12. Lab findings in IDA
•Hb < 11 gm/dl(min 4 Hb estimation MOHFW)
•Peripheral smear - microcytic, hypochromic
•MCV and MCHC are low
•Serum iron is low - < 50 μgm/dl (N 60 -175)
•TIBC is increased - > 400 μgm/dl
•Tests of iron stores
–Serum ferritin is < 100 ngm/dl (1 ng/ml ferritin=8mg of storage iron)
–Stainable iron in the bone marrow is reduced
13. • Currently ferritin value is the best confirmatory test for IDA in pregnancy
• Serum iron is done in morning after an overnight fast(due to diurnal
variation)
• Hepcidin produced by hepatocytes decreases in IDA.
14. Prevention
• Dietary advice and modification
• Iron supplementation of adolescent & non pregnant women
• Treatment of hookworm Infestation
• Iron supplementation in pregnant women
• Food fortification
• Antenatal care for early recognition
15. Management of Anemia
• Oral Iron Therapy
• Prophylactic Iron therapy-30-60mg elemental iron daily with 400 mcg
of folic acid(WHO)
• In areas with <20% incidence elemental iron 120mg+2.8mg folate
once wkly(WHO)
• Deworming of all anemic patients( albendazole 400 MG IN 2nd
trimester)
• Anaemia mukt bharat-50% reduction by 2025
• POSHAN abhiyan-2018-2022,reduce anemia by 3%/yr,60+500 all
pregnants from 2nd trimester to 180 days then 180 days postpartum
16. Iron Requirement in Pregnancy
•2.5mg /day in early pregnancy
•5.5mg /day from 20 -32 weeks
•6 – 8 mg/ day after 32 weeks
•Average 4 mg/ day
17. Side effects of Oral iron
•Nausea
•Vomiting
•Constipation
•Abdominal cramping
•Diarrhoea
18. Reasons for Failure to Respond
•Non compliance
•Concomitant folate deficiency
•Continuous loss of blood through hookworm
infestation or bleeding haemorrhoids
•Co-existing infection
•Faulty iron absorption
•Inaccurate diagnosis
•Non iron deficiency microcytic anaemia
19. Parenteral Iron therapy
• Indicated when the pregnant woman is unable to take iron
due to side effects or is non compliant
• Its main advantage is certainty of administration
• Rise in hemoglobin is similar to oral iron (upto 1gm per wk)
Precaution
Oral Iron to be suspended 48 hours before parenteral therapy
20. Preparation & dosage
• Iron Dextran IM and IV – high molecular wt stable complexes
release iron slowly, can cause anaphylaxis,z track,1.5 mg/kg
• Iron citrate sorbitol IM – less stable, rapid release of iron
• Iron sucrose IV – intermediate stability, rapid metabolism
hence readily available iron. Since they do not form biological
polymers, there are no reactions ,200 mg in 100ml NS
• Iron FCM-approved in 2nd and 3rd trimester,better safey
profile with higher dose availability.1000 mg/250 ml NS
• Others -iron isomaltoside 1000(20 mg/kg),ferumoxytol
24. Blood Transfusion
•Pregnancy <36 wks-hb<5gm/dl or 5-7 gm/dl
•Pregnancy <36 wks-hb<7gm/dl or <4gm/dl
•Hemorrhage hb <6gm/dl
•Hb<7gm/dl in labour or postpartum
•Associated infections
•Packed cells preferred
25. Use of Erythropoetin
•Used in severe anemia & renal failure for significant
increase in Hb and to avoid blood transfusion
•Gynaecological surgeries - preop use of erythropoietin
and Iron Dextran has been shown to avoid the need
for blood tranfusion later
26. Dosage Regimen Erythropoetin
•Inj erythropoetin can be given subcut or iv, 100-150 iu/kg
•On day 1, 3 & 5 along with parenteral iron or day 1, 3 & 5
4000units s/c erythropoetin
•First dose given after subcut sensitivity test
•Adrenaline, hydrocortisone, oxygen to be kept ready
•Produces 3gm% rise in Hb over a 2wk period
27. Management in Labor
• Make patient comfortable, oxygen
• Sedation and analgesia
• Prevent cardiac failure-give furosemide,avoid ergometrine
• Aim to deliver vaginally, cs only if indicated
• Antibiotics
• Cut short second stage
• Active management of third stage
29. treatment
• 500 microgram of folic acid during antenatal and potpartum
along with iron
• In established cases 5mg of folic acid and parenteral iron for
acute anaemia in last month of pregnancy
• Response seen as increase in LDH in 3-4 days and retic count in
6-8 days
• Only indication for transfusion is aph or pph
30. B12 deficiency
• Lab findings same as in folate deficiency
• Vit B12 level < 90 micrograms/l
• Serum homocysteine increased
• Deoxyuridine suppression test differentiates between vitamin
b12 and folate deficiency.
• recommended intake-2mcg/day bef pregnancy,3mcg/day in
pregnancy
• Without neuro-1000mcg im 3 times wk for 2 wks.maintenance
1000 mcg every 3 months
31. Prepregnancy counselling-
1. hb electrophoresis
2. Hydroxyurea stopped before 3 months, folic acid 5mg/day, penicillin, inflenza vaccine
Antenatal
1. Joint workout by hematologist and obstetrician
2. Fetal monitoring from 32 wks
3. Low dose aspirin
4. Partner testing
5. Partial RBC exchange or automated erythrocytapheresis
Labour
Hydration, oxygenation above 94% , infection prevention , Elective induction after 38 weeks,
Puerperium
1. LMWH 7days after VD , 6 wks after LSCS
2. POPS,DMPA,LNG IUS – SAFE contraception
32. •Thalassemia
Preconecption
1. Partner Hb electrophoresis
2. Maternal cardiac,thyroid,glucose level, serum ferritin
3. Desferioxamine to form ferritin level 1000-2000 ng/ml , stopped
during pregnancy
1. ICT
2. CVS 11-13 wks
Puerperium
1. Desferrioxamine restarted within 1wk of puerperium
2. In splenectomised women-OCPs not given as a choice